Diffuse large B-cell lymphoma: new targets and novel therapies

Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Recently approved agents include polatuzumab with bendamustine and rituximab, selinexor, and tafasitamab plus lenalidomide. Three CAR-T cell prod...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheson, Bruce D., Nowakowski, Grzegorz, Salles, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021545/
https://www.ncbi.nlm.nih.gov/pubmed/33820908
http://dx.doi.org/10.1038/s41408-021-00456-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021545/
https://www.ncbi.nlm.nih.gov/pubmed/33820908
http://dx.doi.org/10.1038/s41408-021-00456-w

Ejemplares similares